<DOC>
	<DOCNO>NCT01961232</DOCNO>
	<brief_summary>The investigator test whether addition Pulmonary Hypertension-related biomarkers , measure across pulmonary circulation , standard hemodynamic evaluation Pulmonary Hypertension lead inform choice Pulmonary Hypertension therapy improve patient outcome .</brief_summary>
	<brief_title>Trans-pulmonary Biomarkers Pulmonary Hypertension</brief_title>
	<detailed_description>Eligible participant know suspected Pulmonary Hypertension undergo clinically indicate right heart catheterization may enrol . Clinical data blood sample analyze .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Age ≥ 18 year old Undergoing RHC PH evaluation Anemia define Hgb &lt; 10 g/dL HCT &lt; 30 Pregnancy time RHC ( assessed urine serum pregnancy test day procedure ) Left ventricular ejection fraction ≤ 40 % Atrial fibrillation time RHC ( define telemetry monitor EKG day procedure ) IPF , CTEPH , COPD/OSA dominant etiology PH Patient currently take PH medication longacting nitrate time RHC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>biomarker</keyword>
	<keyword>cardiac</keyword>
	<keyword>circulation</keyword>
	<keyword>heart disease</keyword>
	<keyword>lung disease</keyword>
</DOC>